Journal of Clinical Oncology
Articles in this Issue
Impact of hypofractionated radiotherapy on pathologic response in locally advanced cervical cancer.
e17518 Background: Cervical cancer remains a significant global health burden, particularly in low- and middle-income coun...
Real-world deployment of a multimodal artificial intelligence (AI) model for predicting response to neoadjuvant chemotherapy in early breast cancer.
534 Background: Multimodal AI models integrate morphological information from H&E-stained images with clinical informa...
Induction chemotherapy with nab-paclitaxel and cisplatin versus docetaxel, cisplatin, and fluorouracil followed by chemoradiotherapy in patients with stage III–IVA nasopharyngeal carcinoma: An open-label, noninferiority, randomized, controlled, phase 3 trial.
6013 Background: The docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen is the standard induction therapy regimen for...
Surgical complications and perioperative outcomes following total mesorectal excision in patients with locally advanced rectal cancer treated with short-course radiotherapy and chemo-immunotherapy: Updated data from the phase II Averectal trial.
e15667 Background: Total mesorectal excision (TME) in locally advanced rectal cancer (LARC) is challenging, particularly a...
Outcomes with enfortumab vedotin (EV) rechallenge after disease progression in metastatic urothelial carcinoma.
4578 Background: EV, alone (mono) or with pembrolizumab (EVP), is an established therapy for metastatic urothelial carcino...
A phase I/IIa, image-guided, alpha-particle therapy study of [ <sup>203</sup> Pb]Pb-PSV359 and [ <sup>212</sup> Pb]Pb-PSV359 in patients with solid tumors that are known to be fibroblast activation protein (FAP)–positive.
e15146 Background: PSV359 is a novel theranostic radiopharmaceutical targeting fibroblast activation protein alpha (FAP-α)...
A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an <i>IDH1/2</i> mutation (INDIGO): Updated efficacy and safety.
2010 Background: Grade 2 gliomas with isocitrate dehydrogenase 1/2 mutations (mIDH1/2) are diffuse, slowly progressive, ma...
Trends in lung cancer mortality among U.S. adults aged ≥55 before and after the introduction of immunotherapy: A CDC WONDER Joinpoint-style analysis.
8595 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States. Although sustaine...
Multicenter phase II trial of atezolizumab plus carboplatin and etoposide for extensive-stage small cell lung cancer older patients who underwent geriatric assessment (OLCSG2002 EPAS Trial).
8099 Background: Combination therapy with anti-PD-L1 monoclonal antibodies and chemotherapy (ICI-chemotherapy) is the curr...
Deciphering ctDNA release influencing factors in luminal breast cancer via single-cell spatial mapping.
e12596 Background: Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for detecting and monitoring HR+/HE...
The association of <i>IDH</i> co-mutations with treatment outcomes and overall survival in <i>TP53</i> -mutated acute myeloid leukemia.
6520 Background: In acute myeloid leukemia (AML), TP53 mutations confer a dismal p...
Is more always better?: Outcomes of TIP versus platinum doublet neoadjuvant chemotherapy in high-risk penile cancer.
e17032 Background: The optimal neoadjuvant chemotherapy (NACT) regimen for high-risk penile carcinoma (bulky, bilateral or...
Germline testing in Asian American and Pacific Islander women with breast cancer.
10605 Background: Per the American Cancer Society, the overall breast cancer incidence rate rose 1% per year from 2012 to...
Single-cell circulating tumor cell genomics of KRAS-independent oncogenic sub-populations and longitudinal clonal evolution in metastatic pancreatic adenocarcinoma.
4216 Background: KRAS mutations are a dominant oncogenic driver in metastatic pancreatic ductal adenocarcinoma (mPDAC) and...
Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.
6514 Background: Chemotherapy-free regimens incorporating blinatumomab (blina) and ponatinib have demonstrated promising a...
RAINFOL-03 (ENGOT-EN-31/GOG-3128): A global, phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice of chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and programmed death-ligand 1 inhibition.
TPS5646 Background: Patients with recurrent endometrial cancer (EC) whose disease progresses after platinum-based chemothe...
Early deviations from guideline-concordant care in triple-negative breast cancer: A patient-reported analysis.
e13528 Background: Timely, guideline-concordant care (GCC) is critical to optimize outcomes in triple-negative breast canc...
Real-world treatment patterns and clinical outcomes for patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
e15550 Background: The 5-year follow up results of KEYNOTE-177 established pembrolizumab as a standard first-line treatmen...
Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: A propensity score–matched analysis from a global federated health research network.
7548 Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes an...
Real-world outcomes of Black versus non-Hispanic White women with stage IV HER2-low breast cancer treated with trastuzumab deruxtecan at an urban academic center.
e13102 Background: Black women (BW) experience higher rates of advanced breast cancer and breast cancer mortality compared...
Estimated prevalence of polycythemia vera in the United States (2025-2030): SEER analysis with modeled reporting delay.
e18589 Background: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by overproduction of red blood ce...
Performance of ChatGPT in generating patient-facing cancer survivorship care plans.
1673 Background: Survivorship care plans (SCPs) summarize cancer treatments and provide evidence-based recommendations for...
Large language model–assisted decision-making in multidisciplinary tumor boards for colorectal cancer.
3521 Background: Evolving colorectal cancer management and rising incidence have increased the workload of multidisciplina...
Safety, pharmacokinetics, and immunogenicity of HLX6018, a monoclonal antibody targeting the GARP/TGF-β1 complex, in healthy subjects: A randomized, double-blind, placebo-controlled, phase I clinical study.
2526 Background: HLX6018 is a novel anti-GARP/TGF-β1 monoclonal antibody that inhibits TGF-β1 release and suppresses the a...
Kidney function trajectories in pediatric acute lymphoblastic leukemia.
e18513 Background: Acute kidney injury (AKI) is common in pediatric acute lymphoblastic leukemia (ALL) and can increase th...